Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
Estlin
E J
EJ
Department of Paediatric Oncology,Royal Hospital For Sick Children, St Michael's Hill, Bristol, UK. e.j.estlin@bristol.ac.uk
Lowis
S P
SP
Hall
A G
AG
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015122:Mercaptopurine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D013713:Teniposide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013866:Thioguanine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D005047:Etoposide; D013713:Teniposide; D015122:Mercaptopurine; D013866:Thioguanine; D008727:Methotrexate